ZA200907247B - Stabilization of liquid solutions of recombinant protein for frozen storage - Google Patents

Stabilization of liquid solutions of recombinant protein for frozen storage

Info

Publication number
ZA200907247B
ZA200907247B ZA200907247A ZA200907247A ZA200907247B ZA 200907247 B ZA200907247 B ZA 200907247B ZA 200907247 A ZA200907247 A ZA 200907247A ZA 200907247 A ZA200907247 A ZA 200907247A ZA 200907247 B ZA200907247 B ZA 200907247B
Authority
ZA
South Africa
Prior art keywords
stabilization
recombinant protein
liquid solutions
frozen storage
frozen
Prior art date
Application number
ZA200907247A
Other languages
English (en)
Inventor
Nelly Tsvetkova
Omkar Joshi
Paul Wu
Degian Wang
Arnaud Desponds
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA200907247B publication Critical patent/ZA200907247B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200907247A 2007-04-26 2009-10-15 Stabilization of liquid solutions of recombinant protein for frozen storage ZA200907247B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92669807P 2007-04-26 2007-04-26

Publications (1)

Publication Number Publication Date
ZA200907247B true ZA200907247B (en) 2010-08-25

Family

ID=39926041

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907247A ZA200907247B (en) 2007-04-26 2009-10-15 Stabilization of liquid solutions of recombinant protein for frozen storage

Country Status (15)

Country Link
US (2) US8187799B2 (fr)
EP (1) EP2150264A4 (fr)
JP (1) JP5401446B2 (fr)
KR (2) KR101578561B1 (fr)
CN (2) CN103990116A (fr)
AU (1) AU2008245821B2 (fr)
BR (1) BRPI0810500A2 (fr)
CA (1) CA2683317C (fr)
EC (1) ECSP099704A (fr)
HK (1) HK1198815A1 (fr)
IL (1) IL201508A0 (fr)
MX (1) MX2009011367A (fr)
RU (1) RU2469739C2 (fr)
WO (1) WO2008134310A1 (fr)
ZA (1) ZA200907247B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2244814B1 (fr) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Formulation de vwf recombinant
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2349314B1 (fr) 2008-10-21 2013-02-27 Baxter International Inc. Formulations de vwf recombinant lyophilisé
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
WO2015107222A1 (fr) 2014-01-20 2015-07-23 Octapharma Ag Procédé de fabrication de facteur viii ayant un rapport amélioré de fviii:c/fviii:ag
EP3135334A4 (fr) 2014-06-13 2017-06-21 Toppan Printing Co., Ltd. Procédé de fabrication de corps en forme d'aiguille et corps en forme d'aiguille

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
JPS59134730A (ja) 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
US5576194A (en) 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6790439B1 (en) 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
EP1820516B1 (fr) * 1999-02-22 2013-07-24 University of Connecticut Nouvelles formulations de facteur VIII sans albumine
BR0012429A (pt) 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
JP2005501851A (ja) 2001-08-13 2005-01-20 ハーグリーブス リレイ，マイケル 毒素を除去するための組成物
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
CN101912601B (zh) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제

Also Published As

Publication number Publication date
JP5401446B2 (ja) 2014-01-29
KR20150103333A (ko) 2015-09-09
US20120211698A1 (en) 2012-08-23
BRPI0810500A2 (pt) 2014-10-14
WO2008134310A8 (fr) 2009-12-10
CN101678066B (zh) 2014-09-24
WO2008134310A1 (fr) 2008-11-06
US8187799B2 (en) 2012-05-29
JP2010525071A (ja) 2010-07-22
MX2009011367A (es) 2010-03-22
CN101678066A (zh) 2010-03-24
EP2150264A1 (fr) 2010-02-10
KR20100017354A (ko) 2010-02-16
CN103990116A (zh) 2014-08-20
CA2683317C (fr) 2014-12-16
HK1198815A1 (en) 2015-06-12
AU2008245821A1 (en) 2008-11-06
IL201508A0 (en) 2010-05-31
EP2150264A4 (fr) 2014-09-24
ECSP099704A (es) 2009-11-30
US20100113744A1 (en) 2010-05-06
CA2683317A1 (fr) 2008-11-06
AU2008245821B2 (en) 2013-07-04
RU2469739C2 (ru) 2012-12-20
KR101578561B1 (ko) 2015-12-17
US8536125B2 (en) 2013-09-17
RU2009143493A (ru) 2011-06-10

Similar Documents

Publication Publication Date Title
IL201508A0 (en) Stabilization of liquid solutions of recombinant protein for frozen storage
GB0700523D0 (en) The Stabilisation Of Proteins
ZA201003725B (en) Modulation of protein trafficking
PL2004155T3 (pl) Inhibitory agregacji białek
PL2271660T3 (pl) Stabilizowane ciekłe kompozycje enzymów
LT2324835T (lt) Dializės skysčio kompozicija, apimanti kristalizacijos inhibitorių medžiagas
PL2346356T5 (pl) Płynna kompozycja białkowa o wysokiej zawartości tłuszczu
GB0706304D0 (en) Liquid healing vessels
GB2454268B (en) Crystat for reduced cryogen consumption
EP2235425A4 (fr) Récipient réfrigéré pour des températures de surgélation
GB201000519D0 (en) Refrigerating container for ships
GB0914832D0 (en) Container for liquid storage
FI20085156L (fi) Jäähdytettävä säilytysastia
SI2207790T1 (sl) Biološko aktivni C-terminalni arginin vsebujoči peptidi
GB0626021D0 (en) The stabilisation of proteins
PT2120991E (pt) Tratamento d a hemorragia traumática com oligopéptidos curtos
GB0813840D0 (en) Improved liquid crystal compounds
GB0706217D0 (en) Functional protein crystals
EP2257287A4 (fr) Procédés pour augmenter l' absorption de peptides, de peptidomimétiques et d' autres substrats de protéine de transport gastro-intestinale
EP2370552A4 (fr) Stabilisation de l'essence de pyrolyse (pygas) pour son entreposage
IL189405A0 (en) Stabilization of siva2
ZA201002355B (en) Cold stabilization of wine
GB0811786D0 (en) Global warming monitor
PL378832A1 (pl) Zbiornik retencyjny cieczy
GB0813006D0 (en) The stabilisation of proteins